Want to see PULM full AI Analyst Report?
Top Page
Pulmatrix
(NASDAQ:PULM)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.50
▼(-9.09% Downside)
Action:Reiterated
Date:08/18/26
The score is primarily held down by weak financial performance (near-zero revenue, continued losses, and sharply reduced equity) despite improved cash burn and no debt. Technical indicators also lean negative with the stock below key short-term moving averages and negative MACD. Valuation is not supportive because the company is loss-making (negative P/E) and no dividend yield is provided.
Positive Factors
Debt-Free Balance Sheet
No reported debt reduces interest obligations, refinancing risk, and creditor pressure. This gives the company greater flexibility to direct limited resources toward respiratory drug development, although it does not remove its funding needs.
Negative Factors
No Current Revenue
The absence of a current revenue base means Pulmatrix has not yet demonstrated commercial product demand or recurring operating income. Financial progress therefore remains dependent on successful clinical development and eventual commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
No reported debt reduces interest obligations, refinancing risk, and creditor pressure. This gives the company greater flexibility to direct limited resources toward respiratory drug development, although it does not remove its funding needs.
Read all positive factors
Pulmatrix (PULM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.84M
Dividend YieldN/A
Average Volume (3M)7.19K
Price to Earnings (P/E)―
Beta (1Y)-0.22
Revenue Growth-100.00%
EPS Growth49.19%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.10
Shares Outstanding3,652,285
10 Day Avg. Volume4,700
30 Day Avg. Volume7,194
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.14
Price to Sales (P/S)0.00
P/FCF Ratio-1.50
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.24
Revenue Forecast (FY)$16.45M
Pulmatrix Business Overview & Revenue Model
Company Description
Pulmatrix, Inc. (PULM) is a clinical-stage biotechnology firm focused on creating and advancing inhaled treatments. The company's primary goal is to address significant unmet medical needs in respiratory and other diseases within the United States...
How the Company Makes Money
null...
Pulmatrix Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 7.81M | 7.30M | 6.07M | 5.17M |
| Gross Profit | -38.00K | -38.00K | 640.00K | -8.22M | -12.17M | -10.21M |
| EBITDA | -4.02M | -5.16M | -7.04M | -13.99M | -18.67M | -16.42M |
| Net Income | -4.01M | -5.16M | -9.56M | -14.12M | -18.84M | -20.17M |
Balance Sheet | ||||||
| Total Assets | 3.25M | 4.14M | 9.94M | 33.96M | 40.95M | 58.82M |
| Cash, Cash Equivalents and Short-Term Investments | 2.17M | 4.09M | 9.52M | 19.17M | 35.63M | 53.84M |
| Total Debt | 0.00 | 0.00 | 0.00 | 8.76M | 857.00K | 2.29M |
| Total Liabilities | 689.00K | 329.00K | 996.00K | 15.96M | 9.84M | 11.37M |
| Stockholders Equity | 2.56M | 3.81M | 8.95M | 18.00M | 31.11M | 47.45M |
Cash Flow | ||||||
| Free Cash Flow | -3.91M | -5.43M | -11.11M | -16.66M | -19.44M | -19.87M |
| Operating Cash Flow | -3.91M | -5.43M | -10.72M | -15.98M | -19.36M | -19.73M |
| Investing Cash Flow | 0.00 | 0.00 | -398.00K | -676.00K | -86.00K | -144.00K |
| Financing Cash Flow | 950.00K | 0.00 | 0.00 | 53.00K | 1.23M | 43.48M |
Pulmatrix Risk Analysis
Pulmatrix disclosed 72 risk factors in its most recent earnings report. Pulmatrix reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pulmatrix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $16.66M | -2.53 | -67.85% | ― | ― | 56.99% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $73.03M | -2.49 | -53.86% | ― | -20.00% | 75.26% | |
45 Neutral | $17.73M | -1.15 | -66.69% | ― | -62.70% | -121.27% | |
45 Neutral | $9.32M | -0.24 | -767.07% | ― | ― | 22.10% | |
44 Neutral | $5.84M | -1.39 | -102.06% | ― | -100.00% | 49.19% | |
44 Neutral | $8.58M | -2.25 | -43.95% | ― | 11.90% | 43.46% |
* Healthcare Sector Average
PULM
Pulmatrix
1.53
-3.44
-69.25%
IBIO
Ibio
1.43
0.61
73.33%
LPCN
Lipocine
2.15
-0.83
-27.85%
IMRN
Immuron
1.14
-0.68
-37.36%
CMMB
Chemomab Therapeutics
2.59
-0.82
-24.05%
FBLG
FibroBiologics, Inc.
1.41
-10.99
-88.63%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.